Revised forecast
Fiscal year ending March 2026 · Full yearThe bar length represents the relative magnitude of change, based on the item that changed the most in this document.
Due to sluggish orders resulting from reductions in U.S. biotechnology-related budgets, as well as a cautious stance among research institutions and other organizations, including delays in budget execution and carrying budgets forward to the next fiscal year, sales of clinical-use iPS products and contract services in the Medical Business fell significantly below the previous fiscal year. Operating profit was lower than in the previous fiscal year due to the decrease in net sales and changes in the product mix.
| Item | Details |
|---|---|
| Net Sales | -336 |
| Operating profit | -208 |
| Ordinary income | -46 |
| Profit attributable to owners of the parent | -35 |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Period Covered | Full year |
| Previous-period results | Net sales: ¥960 million; operating loss: ¥400 million; ordinary loss: ¥284 million; net loss: ¥305 million; net loss per share: ¥3.29 |
| Reason for the revision | Due to sluggish orders resulting from reductions in U.S. biotechnology-related budgets, as well as a cautious stance among research institutions and other organizations, including delays in budget execution and carrying budgets forward to the next fiscal year, sales of clinical-use iPS products and contract services in the Medical Business fell significantly below the previous fiscal year. Operating profit was lower than in the previous fiscal year due to the decrease in net sales and changes in the product mix. |
| Consolidated / non-consolidated | Non-consolidated |
Items this document does not state (4)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Against a backdrop of sluggish orders due to reductions in U.S. biotechnology-related budgets, research institutions, mainly in the United States, adopted a cautious stance, including delays in budget execution and carrying budgets forward to the next fiscal year. As a result, sales of clinical-use iPS products and contract services in the Medical Business fell significantly below the previous fiscal year. Operating profit was lower than in the previous fiscal year due to the decrease in net sales and changes in the product mix.